Zhibo Zhang

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Metastatic Colorectal Cancer

Randomized Controlled Trial

Epidermal Growth Factor Receptor

Top Venues

Cancer medicine

Therapeutic advances in medical oncology

Journal of hepatocellular carcinoma

This page only lists publications with an associated author ORCID identifier.

Publications

Jiangyue Lu, Lehui Du, Xiao Lei, Zhibo Zhang
Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy. Cancer medicine (2023)
Jiangyue Lu, Xiao Lei, Pei Zhang, Lehui Du, Zhibo Zhang, Baolin Qu
Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer. Cancer medicine (2023)
Jinzhao Zhai, Jiangyue Lu, Zhibo Zhang, Yuan Wang, Xiaoyan Li, Sujie Zhang, Shuai Mu, Xiaoyu Zhi, Xiangwei Ge, Di Lu, Yi Hu, Jinliang Wang
First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. Cancer medicine 11 (10) (2022)
Shixue Chen, Ziwei Huang, Wangping Jia, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Lijie Wang, Pengfei Cui, Zhibo Zhang, Di Huang, Zhaozhen Wu, Xuan Zheng, Yi Hu
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors. Journal of hepatocellular carcinoma 7 (2020)
Zhibo Zhang, Fan Zhang, Fang Yuan, Ye Li, Junxun Ma, Qiuxiang Ou, Zhefeng Liu, Bo Yang, Lijie Wang, Haitao Tao, Sujie Zhang, Xiaoyan Li, Xiaoyu Zhi, Xiangwei Ge, Hua Bao, Xue Wu, Yi Hu, Jinliang Wang
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Therapeutic advances in medical oncology 12 (2020)